SUNNYVALE, Calif., Sept. 14 /PRNewswire/ -- Molecular Devices, Inc., a long-time leader in bioanalytical systems for microplate analysis, today announced the launch of two new multi-mode detection platforms that expand its portfolio of microplate readers, enabling the company to meet all combinations of customer needs now and into the future.
Both products will be showcased at Miptec 2010, Switzerland, September 20-24, as well as several other 2010 shows including Het, Scanlab, Biotechnica, SBS China, Society for Neuroscience, and American Society for Cell Biology. Please check www.MolecularDevices.com for details.
The SpectraMax® Paradigm® Platform is the only user-upgradeable multi-mode reader on the market today and is ideal for drug discovery research, including high-throughput screening. The FilterMax™ F3 and F5 Series Readers deliver unmatched assay performance compared to similarly priced readers and are ideal for a wide range of life science research applications. Both platforms were developed in response to requests from existing customers, and both are commercially available with shipping to begin in early October.
"With these two new platforms, we now have an ideal microplate reader for any combination of application, detection, and budget needs," said Mark Verheyden, President of Molecular Devices. "We've carefully expanded our portfolio to ensure that we will be able to meet our customers' needs across ever-evolving research environments. By adding the SpectraMax Paradigm and FilterMax™ F Series Platforms to our existing lines of readers, we now offer the most comprehensive line of microplate readers on the market today."
Read What you Want When You Want with the SpectraMax Paradigm Multi-Mode Microplate Reader
The new patent-pending SpectraMax Paradigm Platform is the only multi-mode detection platform on the market today that allows users to upgrade the functionality of their instrument directly—no service call, no factory shipment. Upgrading is as easy as selecting from over 20 mix-and-match detection cartridges and inserting them into one or more of 12 instrument slots. A single cartridge can be changed in less than 2 minutes—the instrument can be fully reconfigured in 10 to 20 minutes. This unmatched flexibility provides a platform that can easily be adapted to meet constantly evolving application needs and ever advancing detection technologies while accommodating most budgets. With multiple detection modes, including AlphaScreen and HTRF, as well as 1536-well microplate compatibility to support high-through screening, the SpectraMax Paradigm Reader is ideal for drug discovery & development, particularly for assay development, lead identification, and lead optimization.
Unmatched Assay Performance is Now Within the Reach of any Life Science Laboratory with the new FilterMax F3 & F5 Multi-Mode Readers
The new, patented FilterMax F Series Platform delivers a unique combination of value, performance, and sensitivity, putting high-performance multi-detection capabilities into the hands of any life science researcher. This unique filter-based platform delivers unmatched assay performance across a broad range of life science applications, and currently offers two models: the F3 with absorbance, fluorescence, and luminescence detection modes and the F5 with those same modes plus fluorescence polarization and time resolved fluorescence modes.
About Molecular Devices: At Molecular Devices we have one focus—our customers. When you become our customer, your needs drive our actions and your success is our concern. Our instruments offer a full spectrum of detection technologies and meet all throughput and content needs. Our goal is to deliver highly relevant bioanalytical products to detect biology, decode data, and drive discovery.
All products are FOR RESEARCH USE ONLY. Not for Use in Diagnostic Procedures.
All trademarks are the property of Molecular Devices, Inc.
|SOURCE Molecular Devices, Inc.|
Copyright©2010 PR Newswire.
All rights reserved